The Baldwin Group Completes Acquisition of Homebuilder Distribution Network From Hippo
ABOUT THE BALDWIN GROUP
The Baldwin Group, the brand name for The Baldwin Insurance Group, Inc. (NASDAQ: BWIN) ('Baldwin') and its affiliates, is an independent insurance distribution firm providing indispensable expertise and insights that strive to give our clients the confidence to pursue their purpose, passion, and dreams. As a team of dedicated entrepreneurs and insurance professionals, we have come together to help protect the possible for our clients. We do this by delivering bespoke client solutions, services, and innovation through our comprehensive and tailored approach to risk management, insurance, and employee benefits. We support our clients, colleagues, insurance company partners, and communities through the deployment of vanguard resources and capital to drive our organic and inorganic growth. The Baldwin Group proudly represents more than three million clients across the United States and internationally. For more information, please visit www.baldwin.com.
ABOUT WESTWOOD INSURANCE AGENCY
Established in 1952, Westwood Insurance Agency LLC is a leading, full-service personal lines agency specializing in builder-sourced homeowners insurance and an indirect subsidiary of The Baldwin Group, the brand name for The Baldwin Insurance Group, Inc. (NASDAQ: BWIN) and its affiliates. Licensed in all 50 states, Westwood has served more than one million homeowners through relationships with leading U.S. homebuilders and top insurance companies. Westwood's unique platform facilitates seamless home closings by connecting builders, carriers, lenders and homebuyers with click-to-bind technology. For more information, please visit www.westwoodinsurance.com.
ABOUT HIPPO
Hippo is a technology-enabled insurance group that leverages Spinnaker, its hybrid fronting carrier, to diversify risk across both personal and commercial lines. Through the Hippo Homeowners Insurance Program, the company applies deep industry expertise and strong underwriting capabilities to deliver tailored, proactive coverage for homeowners. With a flexible portfolio and a disciplined risk management approach, Hippo is well-positioned to adapt to changing market conditions and capitalize on market cycles.
Hippo Holdings Inc. subsidiaries include Hippo Insurance Services, Spinnaker Insurance Company, Spinnaker Specialty Insurance Company, and Wingsail Insurance Company. Hippo Insurance Services is a licensed property casualty insurance agent with products underwritten by various affiliated and unaffiliated insurance companies. For more information, please visit http://www.hippo.com.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release may contain various 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, which represent The Baldwin Group's expectations or beliefs concerning future events. Forward-looking statements are statements other than historical facts and may include statements that address The Baldwin Group's future operating, financial or business performance or The Baldwin Group's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as 'may,' 'might,' 'will,' 'should,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'predicts,' 'projects,' 'potential,' 'outlook' or 'continue,' or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements.
Factors that could cause actual results or performance to differ from the expectations expressed or implied in such forward-looking statements include, but are not limited to, those described under the caption 'Risk Factors' in Baldwin's Annual Report on Form 10-K for the year ended December 31, 2024 and in Baldwin's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), which are available free of charge on the SEC's website at: www.sec.gov, including those risks and other factors relevant to business, financial condition and results of operations. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to The Baldwin Group or to persons acting on The Baldwin Group's behalf are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and The Baldwin Group does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
TD Cowen Reiterates Buy on Alphabet (GOOGL) Ahead of Earnings—Here's Why
Alphabet Inc. (NASDAQ:GOOGL) is one of the . On July 9, TD Cowen analyst John Blackledge reiterated a 'Buy' rating on the stock with a $195.00 price target. The rating affirmation comes ahead of the company's second-quarter 2025 earnings report. 'GOOG 2Q25 Preview: Expect Solid Search & YouTube Growth Amid Resilient Consumer; Our 2Q Digital ad expert call on 7/2 implies GOOG Search strength has cont'd into summer, despite tariff uncertainty." Alphabet Inc. (NASDAQ:GOOGL) is an American multinational technology conglomerate holding company wholly owning the internet giant Google, amongst other businesses. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
37 minutes ago
- Yahoo
Rezolve AI (RZLV) Launches Global Professional Services Division for AI Growth
Rezolve AI PLC (NASDAQ:RZLV) is one of the most popular AI penny stocks to buy according to billionaires. On June 26, the company announced the creation of Rezolve Ai Professional Services, a global growth platform to meet rising demand in the enterprise AI services market. Source: unsplash The company appointed Sauvik Banerjjee to lead the division's efforts. Banerjjee, formerly the Global Commerce Head at Accenture and a founder and CTO at Tata Digital, is now the President of Rezolve Ai Global Professional Services and Chief Digital Officer. The new division will provide a range of services designed to help enterprises effectively integrate and utilize Rezolve's 'Brain Suite' AI technology. These services include C-suite advisory on AI roadmaps, data and architecture readiness assessments, tailored 'Brain Suite' model training and integration, as well as change management and continuous optimization. The creation of this division follows Rezolve's achievement of $70 million in Annual Recurring Revenue (ARR) ahead of schedule, with expectations to exceed $100 million ARR by the end of 2025. The company's platform currently supports over 50 enterprise customers and engages 16.5 million monthly active users across 42 million devices. Rezolve AI PLC (NASDAQ:RZLV) provides generative AI solutions specifically designed for the retail and e-commerce sectors. Its platform enables real-time consumer engagement across millions of devices, powering dynamic search, personalized promotions, and transactional experiences. While we acknowledge the potential of RZLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Defensive Stocks to Buy in a Volatile Market. Disclosure: None. This article is originally published at Insider Monkey. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
43 minutes ago
- Yahoo
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet
Canopy Growth seems unable to overcome the industrywide challenges it faces. Novavax's recent quarterly update, though strong, says little about its prospects. 10 stocks we like better than Canopy Growth › Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so. You should be careful to avoid catching falling knives. Let's consider two stocks that have significantly lagged the market in recent years but could still fall further: Canopy Growth (NASDAQ: CGC) and Novavax (NASDAQ: NVAX). Canopy Growth emerged as a leader in the cannabis industry toward the end of the past decade. The company has significant operations in Canada, the U.S., and various countries worldwide, including Germany. Despite its position in these markets, Canopy Growth has been a profoundly disappointing investment over the past five years. Its latest results provided another example as to why. During the fourth quarter of its fiscal 2025, which ended March 31, Canopy Growth's net revenue declined by 11% year over year to 65 million Canadian dollars ($47.6 million). The company's loss per share for the period was CA$1.43 ($1.05), worse than the CA$1.03 ($0.75) it reported in the prior-year quarter. In fairness, Canopy Growth's troubles aren't entirely its fault. The cannabis industry has been a mess due to legal and regulatory challenges; competition from illicit channels, sometimes even where the product is legal; and oversupply, particularly in Canada, which legalized recreational use of cannabis for adults in 2018. Hardly any pot company has found consistent success over the past five years, despite different focuses, strategies, and executions across the industry. That may suggest the problem is not exclusive to specific companies. No matter whose fault it is, though, Canopy Growth's business is in shambles, and things are not about to get better. True, the company is engaged in cost-cutting efforts while refocusing its portfolio in Canada on in-demand items, such as vapes and pre-rolls. Management predicts that it will achieve positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in "the near-term." Yet, even if Canopy Growth gets there, positive EBITDA would only be a step toward profitability. The company's efforts to reduce expenses may help boost margins in the short term. But it's challenging to envision a path for it to perform well in the long run, given the industry challenges that have led to inconsistent financial results over the past half-decade. Are investors to believe that, after all this time and countless failures across the industry -- both those of Canopy Growth and of others -- the company has finally cracked the code? Convincing the market that that's the case will require more than just positive adjusted EBITDA. I see little reason to expect the pot grower to perform well over the next five years. In fact, I'd expect the stock to sink even further -- and advise investors to stay far away. Examining Novavax's financial results and recent progress may suggest that the stock is a compelling investment opportunity. In the first quarter, the company's revenue was $666.7 million, compared to just $93.9 million for the comparable period of the previous fiscal year. Net income was $518.6 million, compared to a net loss of $147.6 million in the first quarter of 2024. Furthermore, Novavax recently reported positive results from phase 3 studies for its stand-alone influenza vaccine and combination COVID-19/flu vaccine. That's to say nothing of the partnerships it's signed with companies like Sanofi and Takeda Pharmaceuticals, which have paid Novavax for the rights to its COVID vaccines in various countries. But can the company sustain its performance over the long run? Probably not, and here's why. First, the coronavirus vaccine market has been inconsistent and hard to predict. Recent regulatory guidance in the U.S. may further complicate matters, with the Department of Health and Human Services no longer recommending the vaccine for certain populations, including pregnant women and healthy children. It's also worth noting that Novavax has generally played second fiddle to the leaders in this space, Moderna and Pfizer. Novavax's strong financial results in the first quarter are not at all indicative of how it will perform year in and year out. Second, the company's phase 3 wins for its two leading vaccines were not significant achievements. Although they induced strong immune responses in participants, Novavax itself states that these trials were not designed to demonstrate statistical significance. In other words, these results won't support approval. And while they're a good stepping stone to phase 3 studies that would, Novavax is waiting for a partner with big pockets to run these trials. That means it either doesn't have the funds to go at it alone, or management doesn't think doing so without a partner will be worth the investment -- or both. Even if it does find a partner, other companies (including Moderna) have made significant strides in developing competing vaccines. Lastly, the infusion of cash it received from its partnership with Sanofi will eventually run out. The company's business will likely have little to show for itself after that point. All these factors make Novavax unattractive to long-term investors, as the stock could fall much further than it has in the past five years. Before you buy stock in Canopy Growth, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Canopy Growth wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $694,758!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $998,376!* Now, it's worth noting Stock Advisor's total average return is 1,058% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. 2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet was originally published by The Motley Fool
